Analysis
Argenx to Acquire Forte Biosciences for $2.2 Billion | THINKSABIO
Jul 27, 2026 Β· ThinkSabio Inc
Keywords
SEC 13DSEC 13GThinkSabiostocks simplifiedAnalysisstock market 2026institutional holdings
π₯ POWER OF TS! π
π #FBRX Delivers a Blockbuster Breakout! π
From $21.25 (July 09) β $76.48 today
π +260% MASSIVE GAIN in 2 Weeks!!!
π TS Alert Journey:
β
July 10: $43.74 (+105% Gain in 1 Day) (https://t.me/c/2454754655/8899)
β
July 20: $50.76 (+133% Gain in 11 Days) (https://t.me/c/2454754655/9023)
β
July 23: $61.37 (+188% Gain in 14 Days) (https://t.me/c/2454754655/9092)
π’ Today's Big News:
β’ argenx to Acquire Forte Biosciences: Agreed to acquire Forte Biosciences for $77.00 per share in cash, valuing the company at approximately $2.2 billion.
β’ Strategic Pipeline Expansion: The acquisition adds FB102, a first-in-class anti-CD122 antibody, to argenx's immunology pipeline, validating its strong autoimmune potential.
Supporting Factors:
β’ Strong Phase 1b Vitiligo Data with statistically significant efficacy and favorable safety.
β’ Multi-Indication Opportunity: Vitiligo, Celiac Disease & Alopecia Areata.
β’ FDA Fast Track Designation for Celiac Disease.
https://www.thinksabio.com/reports/isr/FBRX
Share this post
π¬ Comments
Loading commentsβ¦
Leave a comment
